Product How it works Pricing Blog FAQ About Contact
Monte Rosa Therapeutics

Monte Rosa Therapeutics (NASDAQ: GLUE) revenue

Monte Rosa Therapeutics reported revenue of $123.7m for fiscal 2025, 63.5% more than in fiscal 2024 ($75.6m).

Fiscal 2025 is the highest of the 3 fiscal years on record for Monte Rosa Therapeutics.

Revenue, in millions of US dollars0.0202375.62024123.72025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$123.7m+63.5%−$54.2m−43.8%
2024$75.6m—−$81.1m−107.3%
2023$0.0m—−$143.3m—

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Monte Rosa Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Monte Rosa Therapeutics ranks 274th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Monte Rosa Therapeutics, 63.5%.

RankCompanyRevenueRevenue growth
272ndLifecore Biomedical$128.9m0.5%
273rdXencor$125.6m13.7%
274thMonte Rosa Therapeutics$123.7m63.5%
275thGyre Therapeutics$116.6m10.2%
276thOraSure Technologies$115.0m−38.1%

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Monte Rosa Therapeutics

How much revenue did Monte Rosa Therapeutics make in fiscal 2025?
Monte Rosa Therapeutics reported revenue of $123.7m for fiscal 2025, compared with $75.6m in fiscal 2024.
What was the best year for revenue at Monte Rosa Therapeutics?
Of its last 3 fiscal years, fiscal 2025, with $123.7m.
Where does Monte Rosa Therapeutics rank in its sector by revenue?
It ranks 274th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Monte Rosa Therapeutics come from?
From the annual report (Form 10-K) that Monte Rosa Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Monte Rosa Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Monte Rosa Therapeutics: the Monte Rosa Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.